logo

For the Inventor, By the Inventor

North Chicago, IL, United States of America

Abbvie Stemcentrx LLC


USPTO Granted Patents = 40

% Expired Patents = 57.5



Forward Citations = 144

Loading Chart...
Loading Chart...

44 inventors (with patents filed for the assignee):

goldMedal Scott J Dylla (28 out of 50 patents)

silverMedal David Y Liu (26 out of 108 patents)

bronzeMedal Orit Foord (25 out of 78 patents)

4.  Robert A Stull (25 out of 44 patents)

5.  Laura Saunders (24 out of 38 patents)

6.  Michael Torgov (19 out of 49 patents)

7.  Hui Shao (17 out of 36 patents)

8.  Alex Bankovich (4 out of 5 patents)

9.  Johannes Hampl (4 out of 5 patents)

10.  Marianne Theresa Santaguida (3 out of 7 patents)

11.  Samuel Williams (3 out of 3 patents)

12.  Mandy Boontanrart (3 out of 3 patents)

13.  Monette Aujay (3 out of 5 patents)

14.  Wade C Anderson (3 out of 4 patents)

15.  Deepti Rokkam (3 out of 21 patents)


Core Competencies:
Anti-DLL3
Antibody Drug Conjugates
Anti-PTK7
Anti-SEZ6
Monoclonal Antibodies
Site-Specific Conjugation
Modulators
Cell Subpopulations
Cancer Treatment
Light Chain Variable Regions
Anti-BMPR1B
Anti-DPEP3

40 patents:

1. 11077203 - Anti-SEZ6 antibody drug conjugates and methods of use (2021-08-03),
2. 11033634 - Light chain variable regions (2021-06-15),
3. 10934359 - Anti-BMPR1B antibodies and methods of use (2021-03-02),
4. 10836831 - Anti-PTK7 antibodies and methods of use (2020-11-17),
5. 10533051 - Anti SEZ6 antibodies and methods of use (2020-01-14),
6. 10478509 - Anti-DLL3 antibody drug conjugates for treating cancer (2019-11-19),
7. 10428156 - Anti-MFI2 antibodies and methods of use (2019-10-01),
8. 10308721 - Anti-DLL3 antibodies and drug conjugates for use in melanoma (2019-06-04),
9. 10189910 - Anti-DPEP3 antibodies and methods of use (2019-01-29),
10. 10137204 - Anti-DLL3 antibody drug conjugates for treating cancer (2018-11-27),
11. 10087258 - Anti-CD324 monoclonal antibodies and uses thereof (2018-10-02),
12. 10053511 - Anti-claudin antibodies and methods of use (2018-08-21),
13. 10047163 - Multispecific constructs (2018-08-14),
14. 10035853 - Site-specific antibody conjugation methods and compositions (2018-07-31),
15. 10017565 - Modulators and methods of use (2018-07-10),
Company Overview
AbbVie Stemcentrx LLC, based in North Chicago, IL, specializes in the development of innovative therapies utilizing advanced biopharmaceutical technologies. The company focuses on antibody-drug conjugates and monoclonal antibodies, particularly targeting DLL3 and PTK7, which are critical in addressing various cancers. Their research emphasizes site-specific conjugation and the modulation of cell subpopulations, aiming to enhance therapeutic efficacy and precision in cancer treatment.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Abbvie Stemcentrx LLC USPTO Patent Assignee Logo
40 Patents

#4 in North Chicago, IL

#472 in Illinois

#8,618 in US

#17,048 in the World

North Chicago, IL (US)
North Chicago, IL, United States of America

Abbvie Stemcentrx LLC

Forward Citations = 144

44 inventors:

goldMedal Scott J Dylla (28 out of 50 patents)

silverMedal David Y Liu (26 out of 108 patents)

bronzeMedal Orit Foord (25 out of 78 patents)

4.  Robert A Stull (25 out of 44 patents)

5.  Laura Saunders (24 out of 38 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abbvie Stemcentrx LLC. Retrieved from https://idiyas.com/company/abbvie-stemcentrx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…